AstraZeneca's FluMist Home, a nasal flu vaccine available for at-home use, aims to improve vaccination rates among children, especially those afraid of needles. Experts discuss its effectiveness and accessibility.
Flu activity in the U.S. is declining, yet hospitalizations remain high. The CDC reports nearing 100 pediatric deaths this season. What does this mean for public health?